Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis
- PMID: 15618189
- PMCID: PMC538925
- DOI: 10.1128/IAI.73.1.494-503.2005
Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis
Abstract
Aspergillus fumigatus causes invasive pulmonary aspergillosis (IPA). This disease is one of the most life-threatening opportunistic infections in immunocompromised patients. The type of immunosuppressive regimen under which IPA occurs has rarely been investigated. In this study, we evaluated various parameters of the innate immune response during the progression of murine IPA induced by the intratracheal administration of A. fumigatus conidia as a function of two immunosuppressive treatments: a corticosteroid and a chemotherapeutic agent. We compared host responses various times after infection in terms of survival, pulmonary production of pro- and anti-inflammatory cytokines, cellular trafficking in the airways, lung injury, respiratory distress, and fungal development. We found that IPA pathogenesis involved predominantly fungal development in mice treated by chemotherapy and an adverse host response in mice treated with a corticosteroid. These previously unrecognized differences should be taken into account in evaluations of the pathogenesis of IPA in animal models.
Figures









Similar articles
-
Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses.J Infect Dis. 1999 Dec;180(6):1957-68. doi: 10.1086/315142. J Infect Dis. 1999. PMID: 10558953
-
Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis.J Immunol. 1999 Feb 1;162(3):1633-40. J Immunol. 1999. PMID: 9973423
-
Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis.Clin Exp Immunol. 2007 May;148(2):382-9. doi: 10.1111/j.1365-2249.2007.03351.x. Epub 2007 Mar 5. Clin Exp Immunol. 2007. PMID: 17335555 Free PMC article.
-
Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen.Clin Microbiol Infect. 2005 Jun;11(6):427-9. doi: 10.1111/j.1469-0691.2005.01143.x. Clin Microbiol Infect. 2005. PMID: 15882191 Review.
-
Pulmonary defense mechanisms against opportunistic fungal pathogens.Immunol Ser. 1989;47:243-71. Immunol Ser. 1989. PMID: 2490078 Review.
Cited by
-
Neutrophil and Macrophage NADPH Oxidase 2 Differentially Control Responses to Inflammation and to Aspergillus fumigatus in Mice.J Immunol. 2022 Nov 15;209(10):1960-1972. doi: 10.4049/jimmunol.2200543. J Immunol. 2022. PMID: 36426951 Free PMC article.
-
Bioluminescent Aspergillus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis.Appl Environ Microbiol. 2008 Nov;74(22):7023-35. doi: 10.1128/AEM.01288-08. Epub 2008 Sep 26. Appl Environ Microbiol. 2008. PMID: 18820063 Free PMC article.
-
Experimental Models of Infectious Pulmonary Complications Following Hematopoietic Cell Transplantation.Front Immunol. 2021 Aug 16;12:718603. doi: 10.3389/fimmu.2021.718603. eCollection 2021. Front Immunol. 2021. PMID: 34484223 Free PMC article. Review.
-
Peptide-based Antifungal Therapies against Emerging Infections.Drugs Future. 2010 Mar;35(3):197. doi: 10.1358/dof.2010.035.03.1452077. Drugs Future. 2010. PMID: 20495663 Free PMC article.
-
Establishment and validation of a predictive nomogram for voriconazole-associated liver injury in lung transplant patients.Int J Clin Pharm. 2025 Jul 16. doi: 10.1007/s11096-025-01946-8. Online ahead of print. Int J Clin Pharm. 2025. PMID: 40668536
References
-
- Balloy, V., J. M. Sallenave, B. Crestani, M. Dehoux, and M. Chignard. 2003. Neutrophil DNA contributes to the antielastase barrier during acute lung inflammation. Am. J. Respir. Cell Mol. Biol. 28:746-753. - PubMed
-
- Becker, M. J., S. de Marie, M. H. Fens, H. A. Verbrugh, and I. A. Bakker-Woudenberg. 2003. Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis. J. Antimicrob. Chemother. 52:428-434. - PubMed
-
- Berenguer, J., M. C. Allende, J. W. Lee, K. Garrett, C. Lyman, N. M. Ali, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1995. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporin and methylprednisolone-induced immunosuppression. Am. J. Respir. Crit. Care Med. 152:1079-1086. - PubMed
-
- Brieland, J. K., C. Jackson, F. Menzel, D. Loebenberg, A. Cacciapuoti, J. Halpern, S. Hurst, T. Muchamuel, R. Debets, R. Kastelein, T. Churakova, J. Abram, R. Hare, and A. O'Garra. 2001. Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus. Infect. Immun. 69:1554-1560. - PMC - PubMed
-
- Cenci, E., A. Mencacci, C. F. d'Ostiani, G. Del Sero, P. Mosci, C. Montagnoli, A. Bacci, and L. Romani. 1998. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J. Infect. Dis. 178:1750-1760. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical